On August 7, 2026 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported its recent updates and financial results for the quarter ended June 30, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"While we were disappointed with the outcome of the Phase 3 FLASH2 clincial study that led to discontinuing the HyBryte (synthetic hypericin) development program, this outcome does not diminish the strength of our broader pipeline or the strategic value of Soligenix," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "We remain focused on evaluating opportunities across our diversified portfolio, including the continued advancement of SGX945 (dusquetide) for Behçet’s disease, which demonstrated promising preliminary efficacy and was generally safe and well-tolerated in our Phase 2 study, as well as our ThermoVax heat-stable vaccine platform."
"With approximately $9.8 million in cash as of June 30, 2026, providing cash runway into the second quarter of 2028, we are well positioned to actively evaluate all strategic options to maximize stockholder value, including but not limited to partnerships, licensing opportunities, merger and acquisition opportunities, government grants and contracts, and the advancement of our existing pipeline. Maintaining our Nasdaq listing is also an important strategic asset that supports these efforts by preserving access to the public capital markets, enhancing our attractiveness to potential strategic partners and acquirers, and providing additional flexibility as we evaluate these opportunities. Consistent with this strategy, we are contuning to seek non-dilutive funding support for the development of our heat-stable Bundibugyo Ebola vaccine program from various sources, including the Coalition for Epidemic Preparedness Innovations (CEPI) and others."
Soligenix Recent Updates
On June 8, 2026, the Company announced that along with the University of Hawaiʻi at Mānoa, it would be applying for CEPI funding to develop a protein-based, thermostable vaccine targeting the Bundibugyo virus by leveraging the thermostability, immunogenicity, and efficacy data demonstrated with its filovirus vaccines. To view this press release, please click here.
On May 26, 2026, in response to a recent Bundibugyo virus outbreak in the Congo, the Company highlighted previous work with the University of Hawaiʻi, which has demonstrated platform compatibility with the key Bundibugyo virus antigen enabling rapid development of a protein-based thermostable subunit vaccine. To view this press release, please click here.
Financial Results – Quarter Ended June 30, 2026
Soligenix had no revenue for the quarter ended June 30, 2026 and 2025, respectively.
Soligenix’s net loss was $2.0 million, or ($0.12) per share, for the quarter ended June 30, 2026, compared to $2.7 million, or ($0.82) per share, for the same prior year period. This decrease in net loss was primarily due to a decrease in in research and development expenses associated with the terminated FLASH2 trial and related HyBryte development activities.
Research and development expenses were $1.0 million as compared to $1.7 million for the quarter ended June 30, 2026 and 2025, respectively. The decrease was primarily due to decreases in costs associated with the terminated FLASH2 trial and related HyBryte development activities.
General and administrative expenses were $1.1 million for the quarter ended June 30, 2026 as compared to $1.1 million for the same period in 2025, relatively flat with a de minimis increase.
As of June 30, 2026, the Company’s cash position was approximately $9.8 million.
(Press release, Soligenix, AUG 7, 2026, View Source [SID1234669875])